Sanjeev Raghuwanshi

5PUBLICATIONS
5CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsMolecular medicineNeonatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 19, 2026
FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers.

Sanjeev Raghuwanshi, Andrei L Gartel

|May 02, 2024
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies.

Sanjeev Raghuwanshi, Xu Zhang, Zarema Arbieva

|Aug 22, 2023
Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance.

I Khan, A Kaempf, S Raghuwanshi

|Jul 23, 2020
Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria.

Durga Shankar Sharma, Sanjeev Raghuwanshi, Narasaiah Kovuru

|Apr 14, 2020
RUNX1 and TGF-β signaling cross talk regulates Ca2+ ion channels expression and activity during megakaryocyte development.

Sanjeev Raghuwanshi, Swati Dahariya, Durga Shankar Sharma

Pageof 1

Frequent Collaborators

3 joint publications

Andrei L Gartel

2 joint publications

Ravi Kumar Gutti

1 joint publications

I Khan

1 joint publications

M Chesnokov